Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Presbyopia

Conditions

Presbyopia, Refractive Error, Eye Diseases, Near Vision

Trial Timeline

Dec 19, 2022 โ†’ Jan 25, 2024

About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine

Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05656027. Target conditions include Presbyopia, Refractive Error, Eye Diseases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05656027Phase 3Completed